Vestal Point Capital LP Purchases New Stake in Zevra Therapeutics, Inc. (NASDAQ:ZVRA)

Vestal Point Capital LP acquired a new position in shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 525,000 shares of the company’s stock, valued at approximately $3,644,000. Vestal Point Capital LP owned 1.00% of Zevra Therapeutics as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in ZVRA. International Assets Investment Management LLC boosted its position in Zevra Therapeutics by 594.0% during the 3rd quarter. International Assets Investment Management LLC now owns 6,940 shares of the company’s stock worth $48,000 after purchasing an additional 5,940 shares during the period. Price T Rowe Associates Inc. MD acquired a new stake in shares of Zevra Therapeutics in the first quarter valued at about $64,000. Hunter Associates Investment Management LLC purchased a new stake in shares of Zevra Therapeutics during the 3rd quarter valued at about $92,000. Intech Investment Management LLC acquired a new position in Zevra Therapeutics during the 3rd quarter worth approximately $95,000. Finally, SG Americas Securities LLC purchased a new position in Zevra Therapeutics in the 3rd quarter worth approximately $105,000. Institutional investors and hedge funds own 35.03% of the company’s stock.

Zevra Therapeutics Stock Performance

Zevra Therapeutics stock opened at $9.50 on Friday. Zevra Therapeutics, Inc. has a 12 month low of $4.20 and a 12 month high of $9.76. The company has a fifty day moving average price of $8.33 and a two-hundred day moving average price of $6.76. The company has a quick ratio of 2.88, a current ratio of 2.88 and a debt-to-equity ratio of 0.84.

Zevra Therapeutics (NASDAQ:ZVRA) last issued its earnings results on Tuesday, November 12th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.25). The business had revenue of $3.70 million during the quarter, compared to the consensus estimate of $5.04 million. Zevra Therapeutics had a negative return on equity of 159.54% and a negative net margin of 342.63%. During the same period in the prior year, the business earned ($0.40) EPS. On average, equities analysts anticipate that Zevra Therapeutics, Inc. will post -1.96 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

ZVRA has been the topic of several analyst reports. Maxim Group lifted their price target on shares of Zevra Therapeutics from $18.00 to $25.00 and gave the stock a “buy” rating in a research note on Tuesday, September 24th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Zevra Therapeutics in a research report on Friday, October 11th. JMP Securities assumed coverage on Zevra Therapeutics in a report on Tuesday, September 24th. They set an “outperform” rating and a $17.00 price objective on the stock. Roth Mkm increased their target price on Zevra Therapeutics from $19.00 to $21.00 and gave the company a “buy” rating in a research note on Tuesday, September 24th. Finally, Canaccord Genuity Group dropped their price target on shares of Zevra Therapeutics from $25.00 to $23.00 and set a “buy” rating for the company in a research note on Thursday, November 14th. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Zevra Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $21.00.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.